These enriched proteins all have established functions in breast cancer literature—maybe with the exception of DYRK1B, whose high expression was only recently associated with worse prognosis in breast cancer,22 potentially because its inhibitory effect on the cell cycle rescues breast cancer cells from apoptosis and cytotoxic drugs.23 Here, DYRK1B is linked to breast cancer.